The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

Nature Medicine

Volumn 1, Issue 3, 1995, Pages 244-248

  Sommer, N ^a   Löschmann, P A ^a   Northoff, G H ^a   Weller, M ^b   Steinbrecher, A ^a   Steinbach, J P ^a   Lichtenfels, R ^a   Meyermann, R ^a   Riethmuller A ^a   Fontana, A ^b   Dichgans, J ^a   Martin, R ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LYMPHOTOXIN; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANIMAL; ANTIDEPRESSIVE AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENCEPHALOMYELITIS, EXPERIMENTAL AUTOIMMUNE; HUMAN; INTERFERON TYPE II; MULTIPLE SCLEROSIS; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RATS; RATS, INBRED LEW; ROLIPRAM; STEREOISOMERISM; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0028955945     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0395-244     Document Type: Article

References (36)

1. Martin, R., McFarland, H.F. & McFarlin, D. Immunological aspects of de- myelinating diseases. Anna. Rev. Immunol. 10, 153-187 (1992).
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661 (1993).
3. Selmaj, K., Raine, C.S., Canella, B. & Brosnan, C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. clin. Invest 87, 949-954 (1991).
4. Selmaj, K. & Raine, C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23, 339-346 (1988).
5. Powell, M.B. et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephali- togenicity. Int. Immun. 2, 539-544 (1990).
6. Kuchroo, V.K. et al. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T-cell clones to mediate experimental allergic encephalomyelitis. J. Immun. 151, 4371-4382 (1993).
7. Chung, I.Y., Norris, J.G. & Benveniste, E.N. Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J. exp. Med. 173, 801-811 (1991).
8. Ruddle, N.H. et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. exp. Med. 172, 1193-1200(1990).
9. Panitch, H.S., Hirsch, R.L., Haley, A.S. & Johnson, K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1, 893-895 (1987).
10. Davis, C.W. Assessment of selective inhibition of rat cerebral cortical calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochim. biophys. Acta 797, 354-362 (1984).
11. Wachtel, H. & Schneider, H.H. Rolipram, a novel antidepressant drag, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 25, 1119-1126(1986).
12. Scott, A.I.F., Perini, A.F., Shering, P.A. & Whalley, L.J. In-patient major depression: Is rolipram as effective as amitriptyline? Eur. f. clin. Pharmac. 40, 127-129 (1991).
13. Suttorp, N., Weber, U., Welsch, T. & Schudt, C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J. clin. Invest 91, 1421-1428 (1993).
14. Semmler, J., Wachtel, H. & Endres, S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int. J. Immunopharmac. 15, 409-413 (1993).
15. Beavo, J.A. & Reifsnyder, D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends pharmac. Sci. 11, 150-155 (1990).
16. McLaughlin, M.M., Cieslinski, L.B., Burman, M., Torphy, T.J. & Livi, G.P. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. J. biol Chem. 268, 6470-6476 (1993)
17. Ichimura, M. & Kase, H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. biophys. Res. Commun. 193, 985-990 (1993).
18. Martin, R, et al. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J.Immun. 148, 1359-1366 (1992).
19. Schmiechen, R., Schneider, H.H. & Wachtel, H. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology 102, 17-20 (1990).
20. Kaulen, P., Brüning, G., Schneider, H.H., Sarter, M., & Baumgarten, H.G. Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3 H] rolipram. Brain Res. 503, 229-245 (1989).
21. Linington, C. et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system, Eur. J. Immun. 23, 1364-1372 (1993).
22. Spengler, R.N. et al. Dynamics of dibutyryl cyclic AMP- and prostaglandin E 2 -mediated suppression of Hpopolysaccharide-induced tumor necrosis factor alpha gene expression. Infect Immun. 57, 2837-2841 (1989).
23. Phipps, R.P., Stein, S.H. & Roper, R.L. A new view of prostaglandin E regulation of the immune response. Immun. Today 12, 349-352 (1991).
24. Racke, M.K. et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. exp. Med. 180, 1961-1966 (1994).
25. Racke, M.K. et al. Evidence for endogenous regulatory function of transforming growth factor-ß 1 in experimental allergic encephalomyelitis. Int. Immun. 4, 615-620 (1992).
26. Herve, P. et al. Phase I II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79, 3362-3368 (1992).
27. Lindsey, J.W. et al. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol 36, 183-189 (1994).
28. Krause, W., Kuhne, G. & Matthes, H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 19, 683-692 (1989).
29. Fleischhacker, W.W. et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorders. Neuropsychobiology 26, 59-64 (1992).
30. Hebenstreit, G.F. et al. Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22, 156-160(1989).
31. Dezube, B.J. et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS clinical trial group. J. Acquir. Immune Defic. Syndr. 6, 787-794 (1993).
32. Stoll, G., Jung, S., Jander, S., van der Meide, P., Hartung, H.P. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J. Neuroimmun. 45, 175-182 (1993).
33. Ben-Nun, A., Wekerle, H., Cohen, I.R. The rapid isolation of clonable antigen-specific T lymphocyte tines capable of mediating autoimmune encephalomyelitis. Eur. J. Immun. 11, 195-199 (1981).
34. Frei, K. et al. Antigen presentation and tumor cytotoxicity by interferon- gamma-treated microgial cells, Eur. J. Immun. 17, 1271-1278 (1987).
35. Swanborg, R.H. Experimental allergic encephalomyelitis. Methods Enzymol 162, 413-421 (1988).
36. Umehara, F., Qin, Y., Wekerle, H., Meyermann, R. Experimental autoimmune encephalomyelitis in the maturing central nervous system. Lab. Invest 62, 147-155 (1990).